

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Kalydeco 50 mg granules

Kalydeco 75 mg granules

Kalydeco 150 mg film coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Film-coated tablets

Each film-coated tablet contains 150 mg of ivacaftor.

Excipient with known effect: each film-coated tablet contains 167.2 mg of lactose monohydrate.

Granules in sachet

Kalydeco 50 mg granules in sachet: each sachet contains 50 mg of ivacaftor.

Excipient with known effect: each sachet contains 73.2 mg of lactose monohydrate.

Kalydeco 75 mg granules in sachet: each sachet contains 75 mg of ivacaftor.

Excipient with known effect: each sachet contains 109.8 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet

Light blue, capsule-shaped tablets, printed with “V 150” in black ink on one side and plain on the other.

Granules in sachet

White to off-white granules approximately 2 mm in diameter.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (CF) aged 6 years and older and weighing 25 kg or more who have one of the following gating (class III) mutations in the *CFTR* gene: *G551D*, *G1244E*, *G1349D*, *G178R*, *G551S*, *S1251N*, *S1255P*, *S549N* or *S549R* (see sections 4.4 and 5.1).

Kalydeco granules are indicated for the treatment of children with cystic fibrosis (CF) aged 2 years and older and weighing less than 25 kg who have one of the following gating (class III) mutations in the *CFTR* gene: *G551D*, *G1244E*, *G1349D*, *G178R*, *G551S*, *S1251N*, *S1255P*, *S549N* or *S549R* (see sections 4.4 and 5.1).

Limitations of use:

Kalydeco is not effective in patients with CF who are homozygous for the *F508del* mutation in the *CFTR* gene.

4.2 Posology and method of administration

Kalydeco should only be prescribed by physicians with experience in the treatment of cystic fibrosis. If the patient's genotype is unknown, an accurate and validated genotyping method should be performed before starting treatment to confirm the presence of an indicated mutation in the *CFTR* gene (see section 4.1).

Posology

Adults, adolescents and children aged 2 years and older should be dosed according to Table 1.

Table 1: Dosing recommendations

| Age/Weight | Dose | Total daily dose |
|---------------------------------------|--|----------------------|
| 2 to 5 years old, <14 kg | 50 mg granules (one sachet) taken orally every 12 hours with fat containing food | 100 mg (two sachets) |
| 2 to 5 years old, ≥14 kg to <25 kg | 75 mg granules (one sachet) taken orally every 12 hours with fat-containing food | 150 mg (two sachets) |
| 6 years and older, ≥25 kg | One 150 mg tablet taken orally every 12 hours with fat-containing food | 300 mg (two tablets) |

The morning and evening dose should be taken approximately 12 hours apart with fat-containing food (see Method of administration).

Missed dose

If 6 hours or less have passed since the missed morning or evening dose, the patient should be advised to take it as soon as possible and then take the next dose at the regularly scheduled time. If more than 6 hours have passed since the time the dose is usually taken, the patient should be advised to wait until the next scheduled dose.

Concomitant use of CYP3A inhibitors

When co-administered with moderate or strong inhibitors of CYP3A the dose should be reduced (see Table 2 for the recommended dose). Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 4.5).

Table 2: Dosing recommendations for concomitant use with mild, moderate or strong CYP3A inhibitors

| Age/Weight | Mild CYP3A inhibitors | Moderate CYP3A inhibitors | Strong CYP3A inhibitors |
|---------------------------------------|-----------------------|---|--|
| 2 to 5 years old, <14 kg | No dose adjustment | One sachet of ivacaftor 50 mg granules once daily | One sachet of ivacaftor 50 mg granules twice a week, approximately 3 to 4 days apart |
| 2 to 5 years old, ≥14 kg to <25 kg | No dose adjustment | One sachet of ivacaftor 75 mg granules once daily | One sachet of ivacaftor 75 mg granules twice a week, approximately 3 to 4 days apart |
| 6 years and older, | No dose adjustment | One morning tablet of ivacaftor 150 mg once daily | One morning tablet of ivacaftor 150 mg twice a week, approximately 3 to 4 days apart |

| Age/ Weight | Mild CYP3A inhibitors | Moderate CYP3A inhibitors | Strong CYP3A inhibitors |
|----------------|-----------------------|---------------------------|-------------------------|
| ≥25 kg | | | |

Special populations

Elderly

Very limited data are available for elderly patients treated with ivacaftor. No dose adjustment specific to this patient population is required (see section 5.2).

Renal impairment

No dose adjustment is necessary for patients with mild to moderate renal impairment. Caution is recommended while using Kalydeco in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or end-stage renal disease (see sections 4.4 and 5.2).

Hepatic impairment

No dose adjustment is necessary for patients with mild hepatic impairment (Child-Pugh Class A). For patients with moderate hepatic impairment (Child-Pugh Class B), a reduced dose of one tablet or one sachet once daily is recommended. There is no experience of the use of Kalydeco in patients with severe hepatic impairment; therefore, its use is not recommended unless the benefits outweigh the risks. In such cases, the starting dose should be one tablet or one sachet every other day or less frequently (see Table 3). Dosing intervals should be modified according to clinical response and tolerability (see sections 4.4 and 5.2).

Table 3: Dosing recommendations for patients with hepatic impairment

| Age/ Weight | Mild (Child-Pugh Class A) | Moderate (Child-Pugh Class B) | Severe (Child-Pugh Class C) |
|---|---------------------------|--|---|
| 2 to 5 years old, <14 kg | No dose adjustment | One sachet of ivacaftor 50 mg once daily | Use is not recommended unless the benefits are expected to outweigh the risks. If used: one sachet of ivacaftor 50 mg every other day Dosing interval should be modified according to clinical response and tolerability. |
| 2 to 5 years old, ≥14 kg to <25 kg | No dose adjustment | One sachet of ivacaftor 75 mg once daily | Use is not recommended unless the benefits are expected to outweigh the risks. If used: one sachet of ivacaftor 75 mg every other day Dosing interval should be modified according to clinical |

| | | | |
|------------------------------|--------------------|---|--|
| | | | response and tolerability. |
| 6 years and older, ≥25 kg | No dose adjustment | One morning tablet of ivacaftor 150 mg once daily | Use is not recommended unless the benefits are expected to outweigh the risks. If used: one morning tablet of ivacaftor 150 mg every other day or less frequently. Dosing interval should be modified according to clinical response and tolerability. |

Paediatric population

Kalydeco is not indicated for children less than 2 years old.

Method of administration

For oral use.

Kalydeco should be taken with fat-containing food.

Food or drink containing grapefruit should be avoided during treatment (see section 4.5).

Film-coated tablets

Patients should be instructed to swallow the tablets whole. The tablets should not be chewed, crushed, or broken before swallowing because there are no clinical data currently available to support other methods of administration.

Granule in sachet

Each sachet is for single use only.

Each sachet of granules should be mixed with 5 mL of age-appropriate soft food or liquid and completely and immediately consumed. Food or liquid should be at room temperature or below. If not immediately consumed, the mixture has been shown to be stable for one hour and therefore should be ingested during this period. A fat-containing meal or snack should be consumed just before or just after dosing.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Only patients with CF who had a *G551D*, *G1244E*, *G1349D*, *G178R*, *G551S*, *S1251N*, *S1255P*, *S549N*, *S549R* gating (class III) mutation or *G970R* in at least one allele of the *CFTR* gene were included in studies 1, 2, 5, and 6 (see section 5.1).

In study 5, four patients with the *G970R* mutation were included. In three of four patients the change in the sweat chloride test was < 5 mmol/L and this group did not demonstrate a clinically relevant improvement in FEV₁ after 8 weeks of treatment. Clinical efficacy in patients with the *G970R* mutation of the *CFTR* gene could not be established (see section 5.1).

Efficacy results from a phase 2 study in patients with CF who are homozygous for the *F508del* mutation in the *CFTR* gene showed no statistically significant difference in FEV₁ over 16 weeks of ivacaftor

treatment compared to placebo (see section 5.1). Therefore, use of Kalydeco in these patients is not recommended.

Effect on liver function tests

Moderate transaminase (alanine transaminase [ALT] or aspartate transaminase [AST]) elevations are common in patients with CF. Transaminase elevations have been observed in some patients treated with ivacaftor. Therefore, assessments of transaminases (ALT and AST) are recommended for all patients prior to initiating ivacaftor, every 3 months during the first year of treatment and annually thereafter. For all patients with a history of transaminase elevations, more frequent monitoring of liver function tests should be considered. In the event of significant elevations of transaminases (e.g., patients with ALT or AST > 5 x the upper limit of normal (ULN), or ALT or AST > 3 x ULN with bilirubin > 2 x ULN), dosing should be interrupted, and laboratory tests closely followed until the abnormalities resolve. Following resolution of transaminase elevations, the benefits and risks of resuming treatment should be considered (see sections 4.2, 4.8 and 5.2).

Hepatic impairment

Use of Kalydeco is not recommended in patients with severe hepatic impairment unless the benefits are expected to outweigh the risks (see sections 4.2 and 5.2).

Renal impairment

Caution is recommended while using Kalydeco in patients with severe renal impairment or end-stage renal disease (see sections 4.2 and 5.2).

Patients after organ transplantation

Kalydeco has not been studied in patients with CF who have undergone organ transplantation. Therefore, use in transplanted patients is not recommended. See section 4.5 for interactions with cyclosporin or tacrolimus.

Interactions with medicinal products

CYP3A inducers

Exposure to ivacaftor is significantly decreased by the concomitant use of CYP3A inducers, potentially resulting in the loss of ivacaftor efficacy; therefore, co-administration of ivacaftor with strong CYP3A inducers is not recommended (see section 4.5).

CYP3A inhibitors

Exposure to ivacaftor is increased when co-administered with strong or moderate CYP3A inhibitors. The dose of ivacaftor must be adjusted when concomitantly used with strong or moderate CYP3A inhibitors (see Table 2 and sections 4.2 and 4.5).

Paediatric population

Cases of non-congenital lens opacities/cataracts without impact on vision have been reported in paediatric patients treated with ivacaftor. Although other risk factors were present in some cases (such as corticosteroid use and exposure to radiation) a possible risk attributable to treatment with ivacaftor cannot be excluded. Baseline and follow-up ophthalmological examinations are recommended in paediatric patients initiating ivacaftor treatment (see section 5.3).

Lactose content

Kalydeco contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Sodium content

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

4.5 Interaction with other medicinal products and other forms of interaction

Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak inhibitor of CYP3A and P-gp and a potential inhibitor of CYP2C9. *In vitro* studies showed that ivacaftor is not a substrate for P-gp.

Medicinal products affecting the pharmacokinetics of ivacaftor

CYP3A inhibitors

Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured as area under the curve [AUC]) by 8.5-fold and increased hydroxymethyl-ivacaftor (M1) to a lesser extent than ivacaftor. A reduction of the Kalydeco dose is recommended for co-administration with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin and clarithromycin (see Table 2 and sections 4.2 and 4.4).

Co-administration with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure by 3-fold and increased M1 to a lesser extent than ivacaftor. A reduction of the Kalydeco dose is recommended for patients taking concomitant moderate CYP3A inhibitors, such as fluconazole, erythromycin, and verapamil (see Table 2 and sections 4.2 and 4.4).

Co-administration of Kalydeco with grapefruit juice, which contains one or more components that moderately inhibit CYP3A, may increase exposure to ivacaftor. Food or drink containing grapefruit should be avoided during treatment with Kalydeco (see section 4.2).

CYP3A inducers

Co-administration of ivacaftor with rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89% and decreased hydroxymethyl ivacaftor (M1) to a lesser extent than ivacaftor.

Co-administration of Kalydeco with strong CYP3A inducers, such as rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. John's wort (*Hypericum perforatum*), is not recommended (see section 4.4).

No dose adjustment is recommended when Kalydeco is used with moderate or weak CYP3A inducers.

Potential for ivacaftor to interact with transporters

In vitro studies showed that ivacaftor is not a substrate for OATP1B1 or OATP1B3. Ivacaftor and its metabolites are substrates of BCRP *in vitro*. Due to its high intrinsic permeability and low likelihood of being excreted intact, co-administration of BCRP inhibitors is not expected to alter exposure of ivacaftor and M1-IVA, while any potential changes in M6-IVA exposures are not expected to be clinically relevant.

Ciprofloxacin

Co-administration of ciprofloxacin with ivacaftor did not affect the exposure of ivacaftor. No dose adjustment is required when Kalydeco is co-administered with ciprofloxacin.

Medicinal products affected by ivacaftor

Administration of ivacaftor may increase systemic exposure of medicinal products that are sensitive substrates of CYP2C9, and/or P-gp, and/or CYP3A which may increase or prolong their therapeutic effect and adverse reactions.

CYP2C9 substrates

Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended during co-administration of warfarin with Kalydeco. Other medicinal products for which exposure may be increased include glimepiride and glipizide; these medicinal products should be used with caution.

Digoxin and other P-gp substrates

Co-administration with digoxin, a sensitive P-gp substrate, increased digoxin exposure by 1.3-fold, consistent with weak inhibition of P-gp by ivacaftor. Administration of Kalydeco may increase systemic exposure of medicinal products that are sensitive substrates of P-gp, which may increase or prolong their therapeutic effect and adverse reactions. When used concomitantly with digoxin or other substrates of

P-gp with a narrow therapeutic index, such as ciclosporin, everolimus, sirolimus or tacrolimus, caution and appropriate monitoring should be used.

CYP3A substrates

Co-administration with (oral) midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5-fold, consistent with weak inhibition of CYP3A by ivacaftor. No dose adjustment of CYP3A substrates, such as midazolam, alprazolam, diazepam or triazolam, is required when these are co-administered with ivacaftor.

Hormonal contraceptives

Ivacaftor has been studied with an oestrogen/progesterone oral contraceptive and was found to have no significant effect on the exposures of the oral contraceptive. Therefore, no dose adjustment of oral contraceptives is necessary.

Paediatric population

Interaction studies have only been performed in adults.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of ivacaftor in pregnant women. Animals studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of ivacaftor during pregnancy.

Breast-feeding

It is unknown whether ivacaftor and/or its metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown excretion of ivacaftor into the milk of lactating female rats. As such, risks to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Kalydeco therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

There are no data available on the effect of ivacaftor on fertility in humans. Ivacaftor had an effect on fertility in rats (see section 5.3).

4.7 Effects on ability to drive and use machines

Kalydeco has minor influence on the ability to drive or use machines. Ivacaftor may cause dizziness (see section 4.8) and, therefore, patients experiencing dizziness should be advised not to drive or use machines until symptoms abate.

4.8 Undesirable effects

Summary of the safety profile

The most common adverse reactions experienced by patients aged 6 years and older are headache (23.9%), oropharyngeal pain (22.0%), upper respiratory tract infection (22.0%), nasal congestion (20.2%), abdominal pain (15.6%), nasopharyngitis (14.7%), diarrhoea (12.8%), dizziness (9.2%), rash (12.8%) and bacteria in sputum (12.8%). Transaminase elevations occurred in 12.8% of ivacaftor-treated patients versus 11.5% of placebo-treated patients.

In patients aged 2 to less than 6 years the most common adverse reactions were nasal congestion (26.5%), upper respiratory tract infection (23.5%), transaminase elevations (14.7%), rash (11.8%), and bacteria in sputum (11.8%).

Serious adverse reactions in patients who received ivacaftor included abdominal pain and transaminase elevations (see section 4.4).

Tabulated list of adverse reactions

Table 4 reflects the adverse reactions observed with ivacaftor in clinical trials (placebo-controlled and uncontrolled studies) in which the length of exposure to ivacaftor ranged from 16 weeks to 144 weeks. The frequency of adverse reactions is defined as follows: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 4: Adverse reactions

| System organ class | Adverse reactions | Frequency |
|---|-----------------------------------|-------------|
| Infections and infestations | Upper respiratory tract infection | very common |
| | Nasopharyngitis | very common |
| | Rhinitis | common |
| Nervous system disorders | Headache | very common |
| | Dizziness | very common |
| Ear and labyrinth disorders | Ear pain | common |
| | Ear discomfort | common |
| | Tinnitus | common |
| | Tympanic membrane hyperaemia | common |
| | Vestibular disorder | common |
| | Ear congestion | uncommon |
| Respiratory, thoracic and mediastinal disorders | Oropharyngeal pain | very common |
| | Nasal congestion | very common |
| | Sinus congestion | common |
| | Pharyngeal erythema | common |
| Gastrointestinal disorders | Abdominal pain | very common |
| | Diarrhoea | very common |
| Hepatobiliary disorders | Transaminase elevations | very common |
| Skin and subcutaneous tissue disorders | Rash | very common |
| Reproductive system and breast disorders | Breast mass | common |
| | Breast inflammation | uncommon |
| | Gynaecomastia | uncommon |
| | Nipple disorder | uncommon |
| | Nipple pain | uncommon |
| Investigations | Bacteria in sputum | very common |

Description of selected adverse reactions

Transaminase elevations

During the 48-week placebo-controlled studies 1 and 2 in patients aged 6 years and older, the incidence of maximum transaminase (ALT or AST) >8 , >5 or >3 x ULN was 3.7%, 3.7% and 8.3% in ivacaftor-treated patients and 1.0%, 1.9% and 8.7% in placebo-treated patients, respectively. Two patients, one on placebo and one on ivacaftor, permanently discontinued treatment for elevated transaminases, each >8 x ULN. No ivacaftor-treated patients experienced a transaminase elevation >3 x ULN associated with elevated total bilirubin >1.5 x ULN. In ivacaftor-treated patients, most transaminase elevations up to 5 x ULN resolved without treatment interruption. Ivacaftor dosing was interrupted in most patients with transaminase elevations >5 x ULN. In all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4).

Paediatric population

The safety data of ivacaftor were evaluated in 34 patients between 2 to less than 6 years of age, 61 patients between 6 to less than 12 years of age and 94 patients between 12 to less than 18 years of age.

The safety profile is generally consistent among paediatric patients aged 2 years and older and is also consistent with adult patients.

The incidence of transaminase elevations (ALT or AST) observed in studies 2,5 and 6 (for patients aged 6 to less than 12 years), and study 7 (patients aged 2 to less than 6 years) are described in Table 5. In the placebo-controlled studies, the incidence of transaminase elevations were similar between treatment with ivacaftor (15.0%) and placebo (14.6%). Peak LFT elevations were generally higher in paediatric patients than in older patients. Across all populations, peak LFT elevations returned to baseline levels following interruption, and in almost all instances where dosing was interrupted for elevated transaminases and subsequently resumed, ivacaftor dosing was able to be resumed successfully (see section 4.4). Cases suggestive of positive rechallenge were observed. In study 7, ivacaftor was permanently discontinued in one patient (see section 4.4 for management of elevated transaminases).

Table 5: Transaminase elevations in patients 2 years to < 12 years treated with ivacaftor

| | n | % of Patients > 3 x ULN | % of Patients >5 x ULN | % of Patients > 8 x ULN |
|----------------|----|----------------------------|---------------------------|----------------------------|
| 6 to <12 years | 40 | 15.0% (6) | 2.5% (1) | 2.5% (1) |
| 2 to <6 years | 34 | 14.7% (5) | 14.7% (5) | 14.7% (5) |

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form <https://sideeffects.health.gov.il>

4.9 Overdose

No specific antidote is available for overdose with ivacaftor. Treatment of overdose consists of general supportive measures including monitoring of vital signs, liver function tests and observation of the clinical status of the patient.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other respiratory system products, ATC code: R07AX02

Mechanism of action

Ivacaftor is a potentiator of the CFTR protein, i.e., *in vitro* ivacaftor increases CFTR channel gating to enhance chloride transport in specified gating mutations (as listed in section 4.1) with reduced channel open probability compared to normal CFTR. The *G970R* mutation causes a splicing defect resulting in little-to-no CFTR protein at the cell surface which may explain the results observed in subjects with this mutation in study 5 (see Pharmacodynamic effects and Clinical efficacy data).

In vitro responses seen in single channel patch clamp experiments using membrane patches from rodent cells expressing mutant CFTR forms do not necessarily correspond to *in vivo* pharmacodynamic response (e.g., sweat chloride) or clinical benefit. The exact mechanism leading ivacaftor to potentiate the gating activity of normal and some mutant CFTR forms in this system has not been completely elucidated.

Pharmacodynamic effects

In studies 1 and 2, in patients with the *G551D* mutation in one allele of the *CFTR* gene, ivacaftor led to rapid (15 days), substantial (the mean change in sweat chloride from baseline through week 24 was -48 mmol/L [95% CI -51, -45] and -54 mmol/L [95% CI -62, -47], respectively) and sustained (through 48 weeks) reductions in sweat chloride concentration.

In study 5 Part 1, in patients who had a non-*G551D* gating mutation in the *CFTR* gene, treatment with ivacaftor led to a rapid (15 days) and substantial mean change from baseline in sweat chloride of -49 mmol/L (95% CI -57, -41) through 8 weeks of treatment. However, in patients with the *G970R-CFTR* mutation, the mean (SD) absolute change in sweat chloride at week 8 was -6.25 (6.55) mmol/L. Similar results to part 1 were seen in part 2 of the study. At the 4-week follow-up visit (4 weeks after dosing with ivacaftor ended), mean sweat chloride values for each group were trending to pre-treatment levels.

In study 7 in patients aged 2 to less than 6 years with a gating mutation on at least 1 allele of the *CFTR* gene administered either 50 mg or 75 mg of ivacaftor twice daily, the mean absolute change from baseline in sweat chloride was -47 mmol/L (95% CI -58, -36) at week 24.

Clinical efficacy and safety

Studies 1 and 2: studies in patients with CF with G551D gating mutations

The efficacy of Kalydeco has been evaluated in two phase 3 randomised, double-blind, placebo-controlled, multi-centre studies of clinically stable patients with CF who had the *G551D* mutation in the *CFTR* gene on at least 1 allele and had FEV₁ ≥40% predicted.

Patients in both studies were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with food containing fat for 48 weeks in addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic sodium chloride was not permitted.

Study 1 evaluated 161 patients who were 12 years of age or older; 122 (75.8%) patients had the *F508del* mutation in the second allele. At the start of the study, patients in the placebo group used some medicinal products at a higher frequency than the ivacaftor group. These medications included dornase alfa (73.1% versus 65.1%), salbutamol (53.8% versus 42.2%), tobramycin (44.9% versus 33.7%) and salmeterol/fluticasone (41.0% versus 27.7%). At baseline, mean predicted FEV₁ was 63.6% (range: 31.6% to 98.2%) and mean age was 26 years (range: 12 to 53 years).

Study 2 evaluated 52 patients who were 6 to 11 years of age at screening; mean (SD) body weight was 30.9 (8.63) kg; 42 (80.8%) patients had the *F508del* mutation in the second allele. At baseline, mean predicted FEV₁ was 84.2% (range: 44.0% to 133.8%) and mean age was 9 years (range: 6 to 12 years); 8 (30.8%) patients in the placebo group and 4 (15.4%) patients in the ivacaftor group had an FEV₁ less than 70% predicted at baseline.

The primary efficacy endpoint in both studies was the mean absolute change from baseline in percent predicted FEV₁ through 24 weeks of treatment.

The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV₁ from baseline through week 24 was 10.6 percentage points (8.6, 12.6) in study 1 and 12.5 percentage points (6.6, 18.3) in study 2. The treatment difference between ivacaftor and placebo for the mean relative change (95% CI) in percent predicted FEV₁ from baseline through week 24 was 17.1% (13.9, 20.2) in study 1 and 15.8% (8.4, 23.2) in study 2. The mean change from baseline through week 24 in FEV₁ (L) was 0.37 L in the ivacaftor group and 0.01 L in the placebo group in study 1 and 0.30 L in the ivacaftor group and 0.07 L in the placebo group in study 2. In both studies, improvements in FEV₁ were rapid in onset (day 15) and durable through 48 weeks.

The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV₁ from baseline through week 24 in patients 12 to 17 years of age in study 1 was 11.9 percentage points (5.9, 17.9). The treatment difference between ivacaftor and placebo for the mean absolute change (95% CI) in percent predicted FEV₁ from baseline through week 24 in patients with baseline predicted FEV₁ greater than 90% in study 2 was 6.9 percentage points (-3.8, 17.6).

The results for clinically relevant secondary endpoints are shown in Table 6.

Table 6: Effect of ivacaftor on other efficacy endpoints in studies 1 and 2

| Endpoint | Study 1 | | Study 2 | |
|--|---|----------|---|----------|
| | Treatment difference ^a (95% CI) | P value | Treatment difference ^a (95% CI) | P value |
| Mean absolute change from baseline in CFQ-R^b respiratory domain score (points)^c | | | | |
| Through week 24 | 8.1 (4.7, 11.4) | < 0.0001 | 6.1 (-1.4, 13.5) | 0.1092 |
| Through week 48 | 8.6 (5.3, 11.9) | < 0.0001 | 5.1 (-1.6, 11.8) | 0.1354 |
| Relative risk of pulmonary exacerbation | | | | |
| Through week 24 | 0.40 ^d | 0.0016 | NA | NA |
| Through week 48 | 0.46 ^d | 0.0012 | NA | NA |
| Mean absolute change from baseline in body weight (kg) | | | | |
| At week 24 | 2.8 (1.8, 3.7) | < 0.0001 | 1.9 (0.9, 2.9) | 0.0004 |
| At week 48 | 2.7 (1.3, 4.1) | 0.0001 | 2.8 (1.3, 4.2) | 0.0002 |
| Mean absolute change from baseline in BMI (kg/m²) | | | | |
| At week 24 | 0.94 (0.62, 1.26) | < 0.0001 | 0.81 (0.34, 1.28) | 0.0008 |
| At week 48 | 0.93 (0.48, 1.38) | < 0.0001 | 1.09 (0.51, 1.67) | 0.0003 |
| Mean change from baseline in z-scores | | | | |
| Weight-for-age z-score at week 48 ^e | 0.33 (0.04, 0.62) | 0.0260 | 0.39 (0.24, 0.53) | < 0.0001 |

| Endpoint | Study 1 | | Study 2 | |
|---|---|---------|---|----------|
| | Treatment difference ^a (95% CI) | P value | Treatment difference ^a (95% CI) | P value |
| BMI-for-age z-score at week 48 ^c | 0.33 (0.002, 0.65) | 0.0490 | 0.45 (0.26, 0.65) | < 0.0001 |

CI: confidence interval; NA: not analyzed due to low incidence of events

^a Treatment difference = effect of ivacaftor – effect of placebo

^b CFQ-R: Cystic Fibrosis Questionnaire-Revised is a disease-specific, health-related quality-of-life measure for CF.

^c Study 1 data were pooled from CFQ-R for adults/adolescents and CFQ-R for children 12 to 13 years of age; Study 2 data were obtained from CFQ-R for children 6 to 11 years of age.

^d Hazard ratio for time to first pulmonary exacerbation

^e In patients under 20 years of age (CDC growth charts)

Study 5: study in patients with CF with non-G551D gating mutations

Study 5 was a phase 3, two-part, randomised, double-blind, placebo-controlled, crossover study (part 1) followed by a 16-week open-label extension period (part 2) to evaluate the efficacy and safety of ivacaftor in patients with CF aged 6 years and older who have a *G970R* or non-*G551D* gating mutation in the *CFTR* gene (*G178R*, *S549N*, *S549R*, *G551S*, *G1244E*, *S1251N*, *S1255P* or *G1349D*).

In part 1, patients were randomised 1:1 to receive either 150 mg of ivacaftor or placebo every 12 hours with fat-containing food for 8 weeks in addition to their prescribed CF therapies and crossed over to the other treatment for the second 8 weeks after a 4- to 8-week washout period. The use of inhaled hypertonic saline was not permitted. In part 2, all patients received ivacaftor as indicated in part 1 for 16 additional weeks. The duration of continuous ivacaftor treatment was 24 weeks for patients randomised to part 1 placebo/ivacaftor treatment sequence and 16 weeks for patients randomised to the part 1 ivacaftor/placebo treatment sequence.

Thirty-nine patients (mean age 23 years) with baseline FEV₁ ≥ 40% predicted (mean FEV₁ 78% predicted [range: 43% to 119%]) were enrolled. Fifty-nine percent (23/39) of them carried the *F508del-CFTR* mutation in the second allele. A total of 36 patients continued into part 2 (18 per treatment sequence).

In part 1 of study 5, the mean FEV₁ percent predicted at baseline in placebo-treated patients was 79.3% while in ivacaftor-treated patients this value was 76.4%. The mean overall post-baseline value was 76.0% and 83.7%, respectively. The mean absolute change from baseline through week 8 in percent predicted FEV₁ (primary efficacy endpoint) was 7.5% in the ivacaftor period and -3.2% in the placebo period. The observed treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) (P<0.0001).

The effect of ivacaftor in the overall population of study 5 (including the secondary endpoints of absolute change in BMI at 8 weeks of treatment and absolute change in the respiratory domain score of the CFQ-R through 8 weeks of treatment) and by individual mutation (absolute change in sweat chloride and in percent predicted FEV₁ at week 8) is shown in Table 7. Based on clinical (percent predicted FEV₁) and pharmacodynamic (sweat chloride) responses to ivacaftor, efficacy in patients with the *G970R* mutation could not be established.

Table 7: Effect of ivacaftor for efficacy variables in the overall population and for specific *CFTR* mutations

| Absolute change in percent predicted FEV ₁ | BMI (kg/m ²) | CFQ-R respiratory domain score (points) |
|--|--------------------------|---|
| Through week 8 | At week 8 | Through week 8 |
| All patients (N=39) | | |
| Results shown as mean (95% CI) change from baseline ivacaftor vs placebo-treated patients: | | |
| 10.7 (7.3, 14.1) | 0.66 (0.34, 0.99) | 9.6 (4.5, 14.7) |

| Patients grouped under mutation types (n) | | |
|--|--|---|
| Results shown as mean (minimum, maximum) change from baseline for ivacaftor-treated patients at Week 8*: | | |
| Mutation (n) | Absolute change in sweat chloride (mmol/L) | Absolute change in percent predicted FEV ₁ (percentage points) |
| | At week 8 | At week 8 |
| <i>G1244E</i> (5) | -55 (-75, -34) | 8 (-1, 18) |
| <i>G1349D</i> (2) | -80 (-82, -79) | 20 (3, 36) |
| <i>G178R</i> (5) | -53 (-65, -35) | 8 (-1, 18) |
| <i>G551S</i> (2) | -68 [†] | 3 [†] |
| <i>G970R</i> [#] (4) | -6 (-16, -2) | 3 (-1, 5) |
| <i>S1251N</i> (8) | -54 (-84, -7) | 9 (-20, 21) |
| <i>S1255P</i> (2) | -78 (-82, -74) | 3 (-1, 8) |
| <i>S549N</i> (6) | -74 (-93, -53) | 11 (-2, 20) |
| <i>S549R</i> (4) | -61 ^{††} (-71, -54) | 5 (-3, 13) |

* Statistical testing was not performed due to small numbers for individual mutations.

[†] Reflects results from the one patient with the *G551S* mutation with data at the 8-week time point.

^{††} n=3 for the analysis of absolute change in sweat chloride.

[#] Causes a splicing defect resulting in little-to-no *CFTR* protein at the cell surface

In part 2 of study 5, the mean (SD) absolute change in percent predicted FEV₁ following 16 weeks (patients randomised to the ivacaftor/placebo treatment sequence in part 1) of continuous ivacaftor treatment was 10.4% (13.2%). At the follow-up visit, 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV₁ from part 2 week 16 was -5.9% (9.4%). For patients randomised to the placebo/ivacaftor treatment sequence in part 1 there was a further mean (SD) change of 3.3% (9.3%) in percent predicted FEV₁ after the additional 16 weeks of treatment with ivacaftor. At the follow up visit, 4 weeks after ivacaftor dosing had ended, the mean (SD) absolute change in percent predicted FEV₁ from Part 2 week 16 was -7.4% (5.5%).

Study 3: study in patients with CF with the *F508del* mutation in the *CFTR* gene

Study 3 (part A) was a 16-week, 4:1 randomised, double-blind, placebo-controlled, parallel-group phase 2 study of ivacaftor (150 mg every 12 hours) in 140 patients with CF aged 12 years and older who were homozygous for the *F508del* mutation in the *CFTR* gene and who had FEV₁ ≥40% predicted.

The mean absolute change from baseline through week 16 in percent predicted FEV₁ (primary efficacy endpoint) was 1.5 percentage points in the ivacaftor group and -0.2 percentage points in the placebo group. The estimated treatment difference for ivacaftor versus placebo was 1.7 percentage points (95% CI -0.6, 4.1); this difference was not statistically significant (*P*=0.15).

Study 4: open-label extension study

In Study 4, patients who completed treatment in studies 1 and 2 with placebo were switched to ivacaftor, while patients on ivacaftor continued to receive it for a minimum of 96 weeks, i.e., the length of treatment with ivacaftor was at least 96 weeks for patients in the placebo/ivacaftor group and at least 144 weeks for patients in the ivacaftor/ivacaftor group.

One hundred and forty-four (144) patients from study 1 were rolled over in study 4, 67 in the placebo/ivacaftor group and 77 in the ivacaftor/ivacaftor group. Forty-eight (48) patients from study 2 were rolled over in study 4, 22 in the placebo/ivacaftor group and 26 in the ivacaftor/ivacaftor group.

Table 8 shows the results of the mean (SD) absolute change in percent predicted FEV₁ for both groups of patients. For patients in the placebo/ivacaftor group, baseline percent predicted FEV₁ is that of study 4 while for patients in the ivacaftor/ivacaftor group, the baseline value is that of studies 1 and 2.

Table 8: Effect of ivacaftor on percent predicted FEV₁ in study 4

| Original study and treatment group | Duration of ivacaftor treatment (weeks) | Absolute change from baseline in percent predicted FEV ₁ (percentage points) | |
|------------------------------------|---|---|--------------------------|
| | | N | Mean (SD) |
| Study 1 | | | |
| Ivacaftor | 48* | 77 | 9.4 (8.3) |
| | 144 | 72 | 9.4 (10.8) |
| Placebo | 0* | 67 | -1.2 (7.8) [†] |
| | 96 | 55 | 9.5 (11.2) |
| Study 2 | | | |
| Ivacaftor | 48* | 26 | 10.2 (15.7) |
| | 144 | 25 | 10.3 (12.4) |
| Placebo | 0* | 22 | -0.6 (10.1) [†] |
| | 96 | 21 | 10.5 (11.5) |

* Treatment occurred during blinded, controlled, 48-week phase 3 study.

[†] Change from prior study baseline after 48 weeks of placebo treatment.

When the mean (SD) absolute change in percent predicted FEV₁ is compared from study 4 baseline for patients in the ivacaftor/ivacaftor group (n=72) who rolled over from study 1, the mean (SD) absolute change in percent predicted FEV₁ was 0.0% (9.05), while for patients in the ivacaftor/ivacaftor group (n=25) who rolled over from study 2 this figure was 0.6% (9.1). This shows that patients in the ivacaftor/ivacaftor group maintained the improvement seen at week 48 of the initial study (day 0 through week 48) in percent predicted FEV₁ through week 144. There were no additional improvements in study 4 (week 48 through week 144).

For patients in the placebo/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was higher in the initial study when patients were on placebo (1.34 events/year) than during the subsequent study 4 when patients rolled over to ivacaftor (0.48 events/year across day 1 to week 48, and 0.67 events/year across weeks 48 to 96). For patients in the ivacaftor/ivacaftor group from study 1, the annualised rate of pulmonary exacerbations was 0.57 events/year across day 1 to week 48 when patients were on ivacaftor. When they rolled over into study 4, the rate of annualised pulmonary exacerbations was 0.91 events/year across day 1 to week 48 and 0.77 events/year across weeks 48 to 96.

For patients who rolled over from study 2 the number of events was, overall, low.

Study 7: study in paediatric patients with CF aged 2 to less than 6 years with G551D or another gating mutation

The pharmacokinetic profile, safety and efficacy of ivacaftor in 34 patients aged 2 to less than 6 years with CF who had a G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R mutation in the CFTR gene were assessed in a 24-week uncontrolled study with ivacaftor (patients weighing less than 14 kg received ivacaftor 50 mg and patients weighing 14 kg or more received ivacaftor 75 mg). Ivacaftor was administered orally every 12 hours with fat-containing food in addition to their prescribed CF therapies.

Patients in study 7 were aged 2 to less than 6 years (mean age 3 years). Twenty-six patients out of the 34 enrolled (76.5%) had a *CFTR* genotype *G551D/F508del* with only 2 patients with a non-*G551D* mutation (*S549N*). The mean (SD) sweat chloride at baseline (n=25) was 97.88 mmol/L (14.00). The mean (SD) faecal elastase-1 value at baseline (n=27) was 28 µg/g (95).

The primary endpoint of safety was evaluated through week 24 (see section 4.8). Secondary and exploratory efficacy endpoints evaluated were absolute change from baseline in sweat chloride through 24 weeks of treatment, absolute change from baseline in weight, body mass index (BMI) and stature (supported by weight, BMI and stature z-scores) at 24 weeks of treatment, and measures of pancreatic function such as faecal elastase-1. Data on percent predicted FEV₁ (exploratory endpoint) were available for 3 patients in the ivacaftor 50 mg group and 17 patients in the 75 mg dosing group.

The mean (SD) overall (both ivacaftor dosing groups combined) absolute change from baseline in BMI at week 24 was 0.32 kg/m² (0.54) and the mean (SD) overall change in BMI-for-age z-score was 0.37 (0.42). The mean (SD) overall change in stature-for-age z-score was -0.01 (0.33). The mean (SD) overall change from baseline in faecal elastase-1 (n=27) was 99.8 µg/g (138.4). Six patients with initial levels below 200 µg/g achieved, at week 24, a level of ≥200 µg/g. The mean (SD) overall change in percent predicted FEV₁ from baseline at week 24 (exploratory endpoint) was 1.8 (17.81).

5.2 Pharmacokinetic properties

The pharmacokinetics of ivacaftor are similar between healthy adult volunteers and patients with CF.

After oral administration of a single 150 mg dose to healthy volunteers in a fed state, the mean (±SD) for AUC and C_{max} were 10600 (5260) ng*hr/mL and 768 (233) ng/mL, respectively. After every 12-hour dosing, steady-state plasma concentrations of ivacaftor were reached by days 3 to 5, with an accumulation ratio ranging from 2.2 to 2.9.

Absorption

Following multiple oral dose administrations of ivacaftor, the exposure of ivacaftor generally increased with dose from 25 mg every 12 hours to 450 mg every 12 hours. When given with fat-containing food, the exposure of ivacaftor increased approximately 2.5- to 4-fold. Therefore, ivacaftor should be administered with fat-containing food. The median (range) t_{max} is approximately 4.0 (3.0; 6.0) hours in the fed state.

Ivacaftor granules (2 x 75 mg sachets) had similar bioavailability as the 150 mg tablet when given with fat-containing food to healthy adult subjects. The geometric least squares mean ratio (90% CI) for the granules relative to tablets was 0.951 (0.839, 1.08) for AUC_{0-∞} and 0.918 (0.750, 1.12) for C_{max}. The effect of food on ivacaftor absorption is similar for both formulations, i.e., tablets and granules.

Distribution

Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1-acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells.

After oral administration of ivacaftor 150 mg every 12 hours for 7 days in healthy volunteers in a fed state, the mean (±SD) apparent volume of distribution was 353 L (122).

Biotransformation

Ivacaftor is extensively metabolised in humans. *In vitro* and *in vivo* data indicate that ivacaftor is primarily metabolised by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately one-sixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than one-fiftieth the potency of ivacaftor and is not considered pharmacologically active.

The effect of the CYP3A4*22 heterozygous genotype on ivacaftor exposure is consistent with the effect of co-administration of a weak CYP3A4 inhibitor, which is not clinically relevant. No dose adjustment of ivacaftor is considered necessary. The effect of CYP3A4*22 homozygous genotype patients is expected to be stronger. However, no data are available for such patients.

Elimination

Following oral administration in healthy volunteers, the majority of ivacaftor (87.8%) was eliminated in the faeces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent. The apparent terminal half-life was approximately 12 hours following a single dose in the fed state. The apparent clearance (CL/F) of ivacaftor was similar for healthy patients and patients with CF. The mean (\pm SD) CL/F for a single 150 mg dose was 17.3 (8.4) L/hr in healthy patients.

Linearity/non-linearity

The pharmacokinetics of ivacaftor are generally linear with respect to time or dose ranging from 50 mg to 250 mg.

Special populations

Hepatic impairment

Following a single dose of 150 mg of ivacaftor, adult subjects with moderately impaired hepatic function (Child-Pugh Class B, score 7 to 9) had similar ivacaftor C_{max} (mean [\pm SD] of 735 [331] ng/mL) but an approximately two-fold increase in ivacaftor $AUC_{0-\infty}$ (mean [\pm SD] of 16800 [6140] ng*hr/mL) compared with healthy subjects matched for demographics. Simulations for predicting the steady-state exposure of ivacaftor showed that by reducing the dosage from 150 mg q12h to 150 mg once daily, adults with moderate hepatic impairment would have comparable steady-state C_{min} values as those obtained with a dose of 150 mg q12h in adults without hepatic impairment. Based on these results, a modified regimen of Kalydeco monotherapy is recommended for patients with moderate hepatic impairment (see section 4.2).

The impact of severe hepatic impairment (Child-Pugh Class C, score 10 to 15) on the pharmacokinetics of ivacaftor has not been studied. The magnitude of increase in exposure in these patients is unknown but is expected to be higher than that observed in patients with moderate hepatic impairment.

For guidance on appropriate use and dose modification see Table 3 in section 4.2.

Renal impairment

Pharmacokinetic studies have not been performed with ivacaftor in patients with renal impairment. In a human pharmacokinetic study, there was minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was recovered in the urine). There was negligible urinary excretion of ivacaftor as unchanged parent (less than 0.01% following a single oral dose of 500 mg). Therefore, no dose adjustments are recommended for mild and moderate renal impairment. However, caution is recommended when administering ivacaftor to patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min) or end-stage renal disease (see sections 4.2 and 4.4).

Race

Race had no clinically meaningful effect on the PK of ivacaftor in white (n=379) and non-white (n=29) patients based on a population PK analysis.

Gender

The pharmacokinetic parameters of ivacaftor are similar in males and females.

Elderly

Clinical studies of ivacaftor as monotherapy did not include sufficient numbers of patients aged 65 years and older to determine whether pharmacokinetic parameters are similar or not to those in younger adults.

Paediatric population

Predicted ivacaftor exposure based on observed ivacaftor concentrations in phase 2 and 3 studies as determined using population PK analysis is presented by age group in Table 9.

Table 9: Mean (SD) ivacaftor exposure by age group

| Age group | Dose | C _{min, ss} (ng/mL) | AUC _{τ, ss} (ng*h/mL) |
|---|-------------|------------------------------|--------------------------------|
| 2- to 5-year-olds (<14 kg) | 50 mg q12h | 577 (317) | 10500 (4260) |
| 2- to 5-year-olds (≥14 kg to <25 kg) | 75 mg q12h | 629 (296) | 11300 (3820) |
| 6- to 11-year-olds [†] (≥14 kg to <25 kg) | 75 mg q12h | 641 (329) | 10760 (4470) |
| 6- to 11-year-olds [†] (≥25 kg) | 150 mg q12h | 958 (546) | 15300 (7340) |
| 12- to 17-year-olds | 150 mg q12h | 564 (242) | 9240 (3420) |
| Adults (≥18 years old) | 150 mg q12h | 701 (317) | 10700 (4100) |

* Values based on data from a single patient; standard deviation not reported.

[†] Exposures in 6- to 11-year-olds are predictions based on simulations from the population PK model using data obtained for this age group.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.

Pregnancy and fertility

Ivacaftor was associated with slight decreases of the seminal vesicle weights, a decrease of overall fertility index and number of pregnancies in females mated with treated males and significant reductions in number of corpora lutea and implantation sites with subsequent reductions in the average litter size and average number of viable embryos per litter in treated females. The No-Observed-Adverse-Effect-Level (NOAEL) for fertility findings provides an exposure level of approximately 4 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the maximum recommended human dose (MRHD). Placental transfer of ivacaftor was observed in pregnant rats and rabbits.

Peri- and post-natal development

Ivacaftor decreased survival and lactation indices and caused a reduction in pup body weights. The NOAEL for viability and growth in the offspring provides an exposure level of approximately 3 times the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy in adult humans at the MRHD.

Juvenile animal studies

Findings of cataracts were observed in juvenile rats dosed from postnatal day 7 through 35 at ivacaftor exposure levels of 0.22 times the MRHD based on systemic exposure of ivacaftor and its metabolites when administered as ivacaftor monotherapy. This finding has not been observed in foetuses derived from rat dams treated with ivacaftor on gestation days 7 to 17, in rat pups exposed to ivacaftor through milk ingestion up to postnatal day 20, in 7-week old rats, nor in 3.5 to 5-month old dogs treated with ivacaftor. The potential relevance of these findings in humans is unknown.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Film-coated tablets

Tablet core

Microcrystalline cellulose

Lactose monohydrate

Hypromellose acetate succinate

Croscarmellose sodium
Magnesium stearate
Sodium lauryl sulfate
Colloidal silicon dioxide

Tablet film coat

Polyvinyl alcohol
Titanium dioxide
PEG 3350
Talc
FD&C Blue #2/Indigo carmine aluminum lake
Carnauba wax

Printing ink

Shellac
Isopropyl alcohol
Iron oxide black
n-butyl alcohol
Propylene glycol
Ammonium hydroxide

Granules in sachet

Lactose monohydrate
Mannitol
Hydroxypropyl methylcellulose acetate succinate
Croscarmellose sodium
Sucralose
Magnesium stearate
Colloidal silicon dioxide
Sodium lauryl sulfate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

Film-coated tablets

The expiry date of the product is indicated on the packaging materials.

Granules in sachet

The expiry date of the product is indicated on the packaging materials.

Once mixed with food, Kalydeco granules have been shown to be stable for one hour.

6.4 Special precautions for storage

Store below 30°C.

6.5 Nature and contents of container

Film-coated tablets

Kalydeco tablets are packaged in a thermoform (Aclar/foil) blister or a high-density polyethylene (HDPE) bottle with a polypropylene closure, foil-lined induction seal and molecular sieve desiccant.

The following pack sizes are available:

- Blister pack containing 56 film-coated tablets
- Bottle containing 56 film-coated tablets

Not all pack sizes may be marketed

Granules in sachet

Packaged in a Biaxially Oriented Polyethylene Terephthalate/Polyethylene/Foil/Polyethylene (BOPET/PE/Foil/PE) sachet.

Pack size of 56 sachets (contains 4 individual wallets with 14 sachets per wallet)

6.6 Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MANUFACTURER

Vertex Pharmaceuticals (Europe) Limited
2 Kingdom Street, London W2 6BD, United Kingdom

8. LICENSE HOLDER

Vertex Pharmaceuticals (U.K.) Limited
7 Rival St., Tel Aviv – Yafo, Israel

9. IMPORTER

Medison Pharma Ltd.
10 Ha-Shiloach Street, Petach Tikva

10. REGISTRATION NUMBER

Kalydeco 50 mg Granules: 159-08-35051
Kalydeco 75 mg Granules: 159-09-35052
Kalydeco 150 mg Film Coated Tablets: 153-89-34269

Revised in December 2021 according to MoH guidelines.